Results 101 to 110 of about 22,974 (229)

The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study [PDF]

, 2015
Lara A. Ray, Spencer Bujarski, Kelly E. Courtney, Nathasha R. Moallem, Katy Lunny, Daniel Roche, Adam M. Leventhal, Steven Shoptaw, Keith G. Heinzerling, Edythe D. London, Karen Miotto   +10 more
openalex   +1 more source

Statement from the frontal fibrosing alopecia international expert alliance: SOFFIA 2024

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 2, Page 210-223, February 2026.
Optimal treatment for frontal fibrosing alopecia (FFA) remains contentious. An international expert panel agreed that highly/ultra‐potent topical steroids were the preferred first‐line topical therapy. Preferred systemic therapies were 5‐alpha reductase inhibitors, followed by hydroxychloroquine.
Nekma Meah, Jane Li, Dmitri Wall, Katherine York, Bevin Bhoyrul, Laita Bokhari, Lachlan Coulthard, Leila Asfour, Leonardo Spagnol Abraham, Daniel Asz‐Sigall, Wilma F. Bergfeld, Regina C. Betz, Ulrike Blume‐Peytavi, Valerie Callender, Vijaya Chitreddy, Andrea Combalia, George Cotsarelis, Brittany Craiglow, Rachita Dhurat, Ncoza Dlova, Jeff Donovan, Andrei Doroshkevich, Samantha Eisman, Paul Farrant, Aida Gadzhigoroeva, Jack Green, Ramon Grimalt, Matthew Harries, Maria Hordinsky, Alan D. Irvine, Victoria Jolliffe, Spartak Kaiumov, Brett King, Steven Kossard, Joyce Lee, Won‐Soo Lee, Nino Lortkipanidze, Amy McMichael, Natasha Atanaskova Mesinkovska, Andrew Messenger, Paradi Mirmirani, Elise Olsen, Seth J. Orlow, Yuliya Ovcharenko, Bianca Maria Piraccini, Rodrigo Pirmez, Adriana Rakowska, Pascal Reygagne, Janet Roberts, Lidia Rudnicka, David Saceda‐Corralo, Jerry Shapiro, Pooja Sharma, Tatiana Silyuk, Poonkiat Suchonwanit, Anita Takwale, Antonella Tosti, W. I. Visser, Sergio Vañó‐Galván, Annika Vogt, Martin Wade, Leona Yip, Abraham Zlotogorski, Cheng Zhou, Rodney Sinclair   +64 more
wiley   +1 more source

Advancing Precision Medicine for Alcohol Use Disorder: Replication and Extension of Reward Drinking as a Predictor of Naltrexone Response

, 2019
Katie Witkiewitz, Corey R. Roos, Karl Mann, Henry R. Kranzler   +3 more
openalex   +1 more source

An Update on Biodegradable Microspheres Loaded with Naltrexone

, 2020
Madhu Bala, Akhil Moudgil, Sanjay Kumar
openalex   +1 more source

Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system

, 2015
Sandra A. Springer, Frederick L. Altice, Shan-Estelle Brown, Angela Di Paola   +3 more
openalex   +1 more source

Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans [PDF]

, 2016
Ana Maqueda, Marta Valle, Peter H. Addy, Rosa María Antonijoan, Montserrat Puntes, Jimena Coimbra, María Rosa Ballester, Maite Garrido, M. J. González, Judit Claramunt, Steven A. Barker, Izabela Lomnicka, Marian Waguespack, Matthew W. Johnson, Roland R. Griffiths, Jordi Riba   +15 more
openalex   +1 more source

Impact of hospital‐administered extended‐release naltrexone on readmission rates for patients with alcohol use disorder [PDF]

Nathaniel M. Singh, Kristin Daniel, Alёna A. Balasanova   +2 more
openalex   +1 more source

Effects of cannabidiol plus naltrexone on motivation and ethanol consumption [PDF]

, 2018
Adrián Viudez‐Martínez, María S. García‐Gutiérrez, Ana Isabel Fraguas‐Sánchez, Ana Isabel Torres‐Suárez, Jorge Manzanares   +4 more
openalex   +1 more source

RATIONALE FOR THE SELECTION OF AUXILIARY COMPONENTS FOR THE NALTREXONE HYDROCHLORIDE NASAL SPRAY

Разработка и регистрация лекарственных средств, 2019
The work is devoted to the development of nasal spray containing naltrexone hydrochloride. Naltrexone in doses of 3-5 mg/day acts on the opioid growth factor receptor (OGFr) and toll-like receptor 4 that makes it promising for use in the complex therapy ...
Y. M. Domnina, S. A. Kedik, V. V. Suslov, E. A. Shnyak   +3 more
doaj  

Bioabsorbable, subcutaneous naltrexone implants mitigate fentanyl‐induced respiratory depression at 3 months—A pilot study in male canines

Physiological Reports
The aim of this study is to determine if extended‐release, bioabsorbable, subcutaneous naltrexone (NTX) implants can mitigate respiratory depression after an intravenous injection (IV) of fentanyl. Six different BIOabsorbable Polymeric Implant Naltrexone
Robert L. Joyner, Joseph A. Hollenbaugh, Donald D'Aquila, Marc Fishman, Steven M. Cohen, Veera Holdai, Jeffrey D. Benner   +6 more
doaj   +1 more source